N early, all cells generate and eject vesicles, and these vesicles constitute major vehicles for intercellular communication. Exosomes, as nanosized vesicles (≈30-100 nm in diameter 1 ), target cell function by delivering proteins, lipids, and nucleic acids. Exosomes are emerging as a valuable source for disease stage-specific information and as fingerprints of disease progression and as potential biomarkers in different pathophysiological states. [2] [3] [4] [5] However, because exosomes provide a major medium of intercellular communication, 6 they likely also impact the treatment of diseases. 7, 8 Recent reports have highlighted the critical application of exosomes as personalized targeted drug delivery vehicles. 6, 9 Exosomes harvested from multipotent mesenchymal stromal cells (MSCs) mediate the restorative therapeutic effects of MSCs for stroke. 10 Here, we review the biogenesis of exosomes and their molecular composition and role as messengers of intercellular communication and describe using exosomes for treatment of stroke. We also focus on therapeutic effects and underlying mechanisms of action of exosomes as therapeutic vectors for stroke 11 but do not discuss the role of exosomes as disease or injury biomarkers. Capitalizing on the function of exosomes as vehicles for intercellular communication in physiological and pathophysiological conditions such as stroke provides a paradigm shift and enormous potential for safe and effective therapeutic approaches for stroke and for other diseases/ injury.
Exosome Biogenesis and Content
Exosomes are highly conserved among most eukaryotic organisms, from microorganisms up to mammals. 12 Exosomes originate from the endocytic route and are formed by the inward budding of the plasma membrane. The membrane of late endosomes invaginates and forms small vesicles that are pinched off into the endosomal space. The internal intraluminal vesicles with their cargo secreted into the extracellular space are exosomes.
Exosome proteins participate in antigen presentation, cell adhesion, and cell structure and motility and are stress regulators, involved in transcription and protein synthesis and in trafficking and membrane fusion. 19 Many functional effects of exosomes may be attributed to the transfer of their RNA and miR content. 17 RNAs and miRs are the most relevant cargo in exosomes in terms of the ability of a small number of molecules to influence several proteins/enzymes within one or more cellular pathways in target cells.
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Exosome Isolation and Storage
Many methods for exosome isolation have been described. 21, 22 They include (1) differential centrifugation coupled with ultracentrifugation 15, 23 ; (2) using anti-EpCAM (epithelial cell adhesion molecule)-coated magnetic beads immunoaffinity pull-down 24, 25 ; (3) density gradient separation 25 ; (4) sequential centrifugal ultrafiltration by tangential flow filtration 26 ; (5) using ExoQuick-TC 27 ; (6) rapid isolation of exosome by alternating current electrokinetic microarray chip device 28 ; and (7) using a commercially available size exclusion chromatography column for rapid vesicle purification. 29 Ultracentrifugationisolated exosomes have the highest protein purity, but the lowest recovery of particles. 30 Specific g-force/k factor usage during differential ultracentrifugation also influences the purity and yield of exosomes. 31 Baranyai et al 32 compared the purity of exosomes using differential ultracentrifugation and size exclusion chromatography. They found that using ultracentrifugation isolation, the diameter of the majority of isolated particles fell into the size range of exosomes; however, albumin was also present in the preparations, when 1 hour of ultracentrifugation at 4°C was applied. 32 Size exclusion chromatography isolation showed good reproducibility and rapid vesicle purification (<10 minutes); however, postcolumn exosome concentration steps resulted in some protein loss and also leads to low exosome recovery and reduced purity (assessed by the particle-to-protein ratio). 29 Van Deun et al, 33 compared 4 methods of exosome extraction: differential ultracentrifugation, OptiPrep density gradient centrifugation, ExoQuick precipitation, and Total Exosome Isolation precipitation. They found that ultracentrifugation and OptiPrep density gradient centrifugation showed better clean exosome preparations measured by CD63-immuno-TEM than ExoQuick and Total Exosome Isolation precipitation. OptiPrep density gradient centrifugation showed the purest exosome preparations. 33 However, Taylor et al 34 indicated that circulating exosomes isolated by ExoQuick precipitation produces exosomal RNA and protein with greater purity and quantity than chromatography, ultracentrifugation, and DynaBeads. Therefore, to date, there is no gold-standard method for exosome isolation, which complicates interlaboratory comparisons of data. 21 Exosome storage conditions (such as temperature and duration) influence the therapeutic utility of exosomes and their stability. Protein and RNA content of exosomes decrease at 10 days of room temperature storage compared with storage at −70 and 4°C. 35 Exosomes are stable at 4°C for short term (within 7 days) and when stored at −80°C for at least 90 days. 25 Storage at below −70°C is the most favorable condition for long-term preservation of fresh exosomes for clinical application and basic research. 35 
Interaction of Exosomes With Target Cells
Exosomes are taken up by target cells by several mechanisms, most of which are mediated by the endocytosis route, such as clathrin-mediated endocytosis, 36 phagocytosis, 37 lipid raftmediated internalization, 38 and macropinocytosis, 39 and by direct fusion with the plasma membrane. 40 Exosomes bind to target cells via ligand-receptor interactions, such as integrins, tetraspanins, and intercellular adhesion molecules. Tetraspanins as a functionally important component of exosomes also have specific effects on distinct cell fission and fusion machineries. 41 After binding, exosomal contents are internalized by recipient cells via fusion with the plasma membrane of recipient cells and direct release of contents into the cytoplasm or by exosome internalization by endocytosis into recipient cells. The exosomal tetraspanin web regulates target cell selection and facilitates tailoring exosomes for drug delivery. 42 Human brain endothelial cell-derived exosomes contain several receptors to carry macromolecules across the blood-brain barrier, including transferrin receptor, insulin receptor, low-density lipoprotein, low-density lipoprotein receptor-related protein, and TMEM30A (a putative antigen for the single-domain antibody), and human brain endothelial cell-derived exosomes act as cell communication vesicles with both brain astrocytes and cortical neurons. 43 Therefore, exosomes are promising tools to target drugs or biological material to specific cells across different biological barriers, and exosomes mediate cell-to-cell interaction.
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Exosome Effects on Immunoresponse
Exosomes communicate with cells, participate in the cascade of antigen presentation, and are implicated in various essential immunologic processes such as immune surveillance. 44 Exosomes derived from dendritic cells are antigen-presenting and have been used for treatment of brain tumor in phase I and II clinical trials. 45, 46 Exosomes can cross the blood-brain barrier and transfer brain antigens to the periphery and regulate the peripheral immune system. 47, 48 Exosomes secreted by resident brain cells in response to pathogenic stimuli also influence bystander cells by the transfer of dysregulated miRs that suppress the expression of essential genes in the recipient cells. 49 Stroke and central nervous system neuroinflammatory diseases, such as multiple sclerosis, regulate peripheral immune response via exosomes. 47, 50 Microglial exosomes and astrocyte exosomes store and release the inflammatory cytokine IL-1β (interleukin-1β). 51, 52 Exosomes also transfer proinflammatory messages from the periphery to recipient brain cells. Balusu et al 53 found that the choroid plexus epithelium cells sense and transmit peripheral inflammatory signals to the brain via the release of exosomes. These choroid plexus epithelium exosomes enter brain parenchyma and are taken up by astrocytes and microglia, inducing miR target repression and inflammatory gene upregulation. 53 Microglia-derived extracellular vesicles can stimulate neuronal activity and participate in the propagation of inflammatory signals. 54 Exosomes isolated from circulating immune cells from conditions of environmental enrichment increase oligodendrocyte progenitor cell differentiation into myelinating cells in cultured hippocampal slices and promote myelination in vivo when intranasally administered to naive rats. 55 Thus, exosomes as mediators of neuroinflammation may impact stroke outcome. 49 
Exosome Effects on Thrombosis
Circulating exosomes participate in the coagulation cascade by providing a surface for the assembly of clotting factors. 56 In intracerebral hemorrhage, cerebrospinal fluid and plasma procoagulant microvesicle/exosomes levels are significantly increased and may contribute to stroke pathogenesis. 57 Platelet microvesicles/exosomes have 50-to 100-fold higher specific procoagulant activity than activated platelets. 58 Circulating microvesicles/exosomes derived from endothelial cells and blood cells may promote procoagulant activity and thrombin generation. 59 However, compared with microvesicles and apoptotic vesicles, exosomes have reduced coagulation and immunogenic effects. 60 Manipulating thrombosis and the coagulation cascade via exosomes as an intervention for ischemic stroke warrants investigation.
Therapeutic Effects of Exosomes on Stroke
Exosomes transport cell type-specific molecular cargo extracellularly and over large distances. In addition, the same exosomes may evoke differential response in different cells.
Neural released exosomes not only regulate the onset and progression of neurodegenerative and neuroinflammatory diseases but also may play a role in the regeneration and remodeling of the nervous system after stroke. 61 Neural secreted exosomes contribute to local synaptic plasticity and also influence neuronal networks by long-range communication within the central nervous system. Therefore, by inhibiting their release from diseased cells and by manipulating their cargo to enable shuttling of secretory RNA, miR, or molecules such as cytokines, chemokines, and growth factors, 62 exosomes may function as therapeutic agents. 56 
Advantages of Using Stem Cell-Derived Exosomes for Stroke Therapy
Cell-based therapies for stroke improve neurological outcome. [63] [64] [65] [66] The mechanisms of cell-based therapy-induced therapeutic effects after stroke are not mediated via cell replacement or transplanted cell differentiation into brain cells. 14, 66 Secreted paracrine factors from stem cells are the principal mechanism underlying their therapeutic action in stroke. 14 Using stem cell-secreted paracrine factors and cell-free therapy are likely safer alternatives in promoting brain plasticity after stroke and in neurodegenerative disease. Recently, a variety of cell types have been shown to secrete paracrine factors that are contained within membrane vesicles, such as exosomes, microvesicles, ectosomes, membrane particles, and apoptotic bodies. 18 Extracellular vesicles have emerged as important mediators of intercellular communication, being involved in the transmission of biological signals between cells. 56 Treatment of stroke and neural injury with extracellular vesicles, that is, exosomes, harvested from MSCs, rather than the exosome parent MSCs, supplants the therapeutic benefits of administration of the parent MSCs. 8, 10 Exosomes are specifically internalized by recipient cells, which avoids a multiplicity of potential concerns associated with administration of living cells, and exosomes provide therapeutic benefit, at least the equivalent of their cellular source. Compared with cell therapy, the advantages of exosome-based therapy include 9, 14 (1) low immunogenicity 56 ; (2) no vascular obstructive effect and reduced risk of secondary microvascular thrombosis 14 ; (3) systemically injected exosomes are able to cross the blood-brain barrier and enter the brain parenchyma 67, 68 ; (4) the potential to develop large-scale cellular factories of engineered therapeutic vesicles 17 ; (5) exosomes have higher surface/volume ratio and amplify ligand-gated signaling pathways and the transfer of biomolecules from stem cells to target tissues; and (6) ability to readily modify exosome miR content. Here, we review the possible application of exosomes for the treatment of stroke, to provide a safe and effective alternative to cell-based therapy. 7, 69 In the following section, we discuss exosome therapy for stroke, which is summarized in Figure. 
MSC-Exosome for Treatment of Stroke
Compared with other cell types, the MSC is a prolific exosome producer. 70 Using proteomic analysis, Otero-Ortega et al 67 identified >2000 proteins in MSC-exosome (MSC-Exo), many of which may be implicated in brain repair. MSCs induce neurological recovery poststroke and neural injury, primarily by paracrine effects via MSC-secreted exosomes, which mediate restorative actions of MSCs.
10,71-73 MSC-Exos taken up by endothelial cells, dose dependently increase endothelial cell proliferation, migration, and capillary tube formation, as well as impair T-cell function by inhibiting T-cell proliferation in vitro. 74 Systemically injecting bone marrow-derived MSC-Exo at 1 day after ischemic stroke or traumatic brain injury significantly improves functional outcome, as well as enhances angiogenesis, neurogenesis, and neurite remodeling in rats. 10, [75] [76] [77] [78] Similarly, human MSC-Exo treatment of stroke increases long-term neuroprotection, promotes neuroregeneration, enhances neurological recovery, and modulates peripheral poststroke immune responses but does not affect cerebral immune cell infiltration in mice. 79 MSC-Exos significantly improve functional outcome and reduce structural injury and show promise in treating global hypoxic-ischemic injury of the fetal brain. 80 Human MSC-Exo treatment dose dependently reduces brain neuroinflammation after traumatic brain injury in mice 81 and significantly ameliorates inflammationinduced neuronal cellular degeneration, reduces microgliosis, prevents reactive astrogliosis, and improves functional recovery in traumatic brain injury animals. 82, 83 Adipose-derived MSC-Exo treatment initiated at 3 hours after ischemic stroke was safe, decreasing lesion volume, increasing angiogenesis, demonstrating anti-inflammatory and immunomodulatory capacity, and improving neurological function in rats. 84 Intravenous administration of MSC-Exos to rats subjected to intracerebral hemorrhage significantly promotes white matter/axonal remodeling identified by fiber tract integrity, white matter repair, and axonal sprouting and decreases neurological functional deficits compared with the control group at 28 days after intracerebral hemorrhage. 67 
Multicellular Sources of Microparticles or Exosomes as a Treatment of Stroke
In addition to MSC-Exo, exosomes derived from other cell types also induce neuroprotective and neurorestorative effects after stroke. Exosomes derived from human adipose-derived stem cells increase expression of protein kinase CδII in immortalized mouse hippocampal cell line and increase neuronal survival and proliferation. 85 Platelet-derived microparticles dose dependently increase endogenous neural stem cell proliferation, neurogenesis, and angiogenesis in the ischemic brain and significantly improve neurological functional outcome after ischemic stroke in rats. 86 Microparticles derived from activated platelets contain a variety of growth factors augmenting endogenous neural progenitor cell proliferation and neurovascular remodeling, which may be utilized for stroke therapy. 86, 87 Altmann et al 88 showed that secretomes derived from rat and human apoptotic mononuclear cells also induce neuroprotective effects identified by decreased lesion volume and improved functional neurological outcome. Therefore, exosomes and microvesicles derived from a variety of cells induce angiogenesis, suppress apoptosis, stimulate cell proliferation, promote neurogenesis and synaptic plasticity, deliver immunomodulatory signals, and recruit and reprogram cells and restorative events that in concert improve functional recovery after stroke.
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Exosome Treatment Effects by Transfer of miR
Exosomes contain miRs that play important roles in cell function, disease, and immunomodulation. 7, 8, 89 Systemic administration of MSC-Exos improve neurological functional outcome in animal models of stroke, impacting post-transcriptional gene expression and ensuing protein expression in their target cells via transfer of miRs. 76 miRs are short sequences of noncoding RNA that function in RNA silencing and post-transcriptional regulation of gene expression. 90 Among their myriad of functional properties, miRs also regulate neurovascular remodeling, inflammation, and stem cell biology. 91 We also note that MSCharvested exosomes also stimulate endogenous brain cells to subsequently release miRs, in a chain reaction-like manner, ultimately promoting brain plasticity after stroke. 92 In addition, MSCs inhibit macrophage activation by shedding miR-containing exosomes. 89 In vitro data show that exosomes derived from environmental enrichment serum promote oligodendrocyte precursor cell differentiation into myelinating cells and reduce oxidative stress. 55 MSC-Exos promote axonal growth, and inhibition of argonaut 2 protein (a primary miR machinery protein) abolishes MSC-Exos-induced axonal growth. 75 MSCs communicate with brain parenchymal cells and regulate neurite outgrowth by transfer of miRs, such as miR-133b, to neural cells via exosomes. 76 Collectively, these data demonstrate that exosomes mediate their functional benefit in stroke at least partially by the transfer of miRs to parenchymal cells.
Modification of Exosomes
Exosomes have low toxicity, high stability in the circulation, and high efficiency of transport to donor cells. Modified exosomes have been used as vehicles to transport exogenous chemical compounds to recipient cells. Exosomes are valuable for the delivery of RNA interference and miR regulatory molecules, in addition to other single-stranded oligonucleotides. 93 Intravenous administration of neuronal-targeted exosomes loaded with specific siRNA knocked down their target genes in neurons. 94 Curcumin, an anti-inflammatory agent, can be encapsulated in exosomes. 95 Intranasal administration of curcuminencapsulated exosomes in ischemic stroke mice significantly reduced astrogliosis and increased the expression of NeuN (feminizing locus on X-3, Fox-3, Rbfox3, or hexaribonucleotide binding protein-3) and vascular endothelial tight junction proteins when compared with nontreated stroke mice. 95 Exosomes also contain distinct subsets of miRs depending on the cell type source. 96 Modulation of miRs within stem cells and thereby within exosomes derived from the parent cell may enhance exosome-induced therapeutic efficacy. MSC-Exo can be enriched with specific miRs to enhance recovery of injured tissues. 8, 14 MSCs release functional small RNAs via their exosomes. 10, [71] [72] [73] In vitro, the miR-17 to 92 cluster promotes oligodendrogenesis, neurogenesis, and axonal outgrowth. 97 Treatment of stroke in rat with MSC-Exo and miR-17 to 92 enriched MSC-Exo both significantly improved neurological functional recovery, but miR-17 to 92 cluster enriched exosome treatment induced significantly more improvement of functional outcome and enhancement of neurogenesis, oligodendrogenesis, and neuronal dendrite plasticity in the ischemic brain than the control MSC-Exo treatment. 97 Tailored exosomes derived from MSCs further enhance neurite growth via the phosphatase and tensin homologue/mammalian target of rapamycin signals by increasing the miR-17 to 92 cluster. 98 Exosomes derived from miR133b-overexpressed MSCs and miR-17 to 92 cluster enriched exosomes significantly increase brain plasticity and neurological functional recovery after stroke compared with MSC-Exotreated stroke rats. 97, 99 In vitro data also show that exosomes harvested from astrocytes subjected to oxygen glucose deprivation treated with miR-133b-overexpressing MSC-Exo significantly increased neurite outgrowth in cultured primary cortical neurons compared with the exosomes derived from oxygen glucose deprivation astrocytes subjected to MSC-Exo-control. Thus, in vivo and in vitro data suggest that modulating miR content of exosome may be an effective means to amplify the therapeutic effects of exosomes for the treatment of stroke and neurological injury, as well as degenerative diseases. 8 
Caveats and Future Studies
Although exosomes exhibit promising therapeutic effects, exosome-based therapy for stroke has just recently emerged, and many additional studies are warranted to move this therapy to the clinic. Among the considerations and studies to be performed are the following: (1) scaling production of exosomes for human clinical trials will be required. Recent publications suggest that these production and scaling methods are actively being pursued. 21, 22 In addition, cell culture conditions and storage methods may have a major impact on the exosome content and their functionality. Appropriate exosome isolation methods, storage, and functional read-out systems need to be standardized. (2) Exosome content, function, and activity depend on the generating cells of origin. Therefore, exosome cell source, including age, sex, comorbidities, and other factors associated with the exosome-generating cells should be optimized. (3) Although initial preclinical studies have shown that a single dose of exosomes administered poststroke is highly efficacious in promoting neurological recovery, we cannot exclude the possibility that multiple dosing, particularly for different types of strokes, may further improve neurological outcomes. (4) Doseresponse and therapeutic window studies are required. Given the reported extended therapeutic window for treatment of stroke with cell-based therapies, exosomes may likewise provide an extended therapeutic window. Previous studies have shown that exosome treatment initiated at 24 hours after brain hemorrhage or ischemic stroke significantly improves functional outcome, decreases lesion volume, and promotes axonal/white matter remodeling for both hemorrhage and stroke. 10, 67, 76, 79, 97, 99 Adiposederived mesenchymal stem cell-derived exosome treatment of stroke initiated at 50 minutes or 3 hours after stroke reduced lesion volume and enhanced neurological recovery in rat. 84 Thus, exosome treatment of stroke not only induces neurorestoration but also promotes neuroprotection. However, some therapeutic interventions provide therapeutic benefit in the acute phase of stroke but impair regeneration in the chronic phase and vice versa. 100 Therefore, investigation of the optimal timing of exosome therapy, which may be affected by the parental cell source, is required. (5) Of primary importance is the performance of safety studies for stroke using exosomes. These studies should include safety in patients with comorbidities. Particularly, studies should be performed to ensure that the restorative exosomes are not oncogenic and further promote tumor growth. Enhancing tissue regeneration after stroke in the central nervous system may increase the risk to activate cancer. 100 Induction of neurovascular remodeling is itself associated with angiogenic and cell proliferative events. 101 In addition, exosomes contain many miRs, such as miR-9, miR-223, and miR-126, which not only induce neural repair or axonal growth responses but also closely linked with oncogenesis. [102] [103] [104] [105] Potential oncogenic features of extracellular vesicles or exosomes are being addressed in the literature. 106 Further studies, however, are warranted to evaluate the oncogenic potential of restorative therapy for stroke. Therefore, safety, time window, dose-response, multiple dosing, and oncogenic potential studies, among others, are required for effective and safe translation of this promising restorative and neuroprotective therapeutic approach for the treatment of stroke.
Conclusions
Exosomes have multifaceted roles in the regulation of physiological and pathological processes and importantly may also function as therapeutic agents. Exosomes derived from different cells can induce neuroprotection and neurorestorative effects by modulating gene, protein, and miR expression in their target cells and tissues. Exosomes from specific cells, such as MSCs, and likely other cells, reduce inflammation and increase angiogenesis, neurogenesis, and white matter remodeling after stroke. Modified exosomes can be used as vehicles to transport exogenous genes, proteins, and chemical compounds to recipient cells. Modulation of genes and miRs in exosome parent cells enhances exosome-induced therapeutic efficacy. 72, 76, 97 Therefore, exosomes may potentially be used as personalized targeted drug delivery vehicles. 6 ,9 However, we should cautiously and carefully develop this promising therapy. Safety, time window, and dose-response studies are just a part of the range of investigations that will be performed before the translation of exosomes into the clinic for the treatment of stroke and likely other forms of neurological injury and degenerative diseases.
